Lisata Therapeutics
Company
Lisata Therapeutics develops one asset, in phase 2 (MAR002 in acromegaly). Mostly other acting on Insulin/IGF-1 signalling and IGF1.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 2
- Signals
Pipeline
1Suppression of IGF-1
Phase 2, Other, Insulin/IGF-1 signalling, IGF1, acromegaly, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- People1
- Signals2
- Similar companies6